The UK government’s Global AMR Innovation Fund (GAMRIF) will invest up to £39 million in cutting-edge research. Efforts to create novel treatments to combat antimicrobial resistance (AMR), also known as the “silent killer.”
Antimicrobial resistance (AMR), in which bacteria have developed to the point. Where antibiotics and other conventional therapies are no longer effective against infections. It is a silent killer that claims millions of lives each year around the world. With one in every five of these deaths occurring in children under the age of five.
Up to £24 million over four years has been awarded as part of this new funding package to strengthen the UK’s partnership with CARB-X. A global AMR research initiative, to support the continued early development of invaluable new antibiotics, vaccines, and rapid diagnostics. And other products to combat life-threatening drug-resistant infections and prevent death and disease around the world.
The UK has already committed £20 million of its ringfenced Official Development Assistance (ODA) budget to the programme. This has led to CARB-X investing approximately £40 million in the UK’s world-leading science and innovation sector.
In addition to the CARB-X award, GAMRIF is spending £5 million on the worldwide Antibiotic R&D Partnership (GARDP). Over a two-year period to develop – and assure worldwide access to – novel antibiotic treatments against significant global health priority.
The statement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland. And Development Minister Andrew Mitchell attends a health leadership and climate change event in conjunction with the WHA. As part of Minister Quince’s talk to the WHA, they will announce the introduction of the UK government’s Global Health Framework for 2023-2025.
